NCT06048536View on ClinicalTrials.gov

Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch

PHASE2CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

December 22, 2023

Primary Completion Date

January 18, 2024

Study Completion Date

January 18, 2024

Conditions
Contraception
Interventions
DRUG

MR-130A-01 Transdermal patch

MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.

DRUG

MR-130A-01 Transdermal patch

MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.

DRUG

MR-130A-01 Transdermal patch

MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period

DRUG

MR-130A-01 Transdermal patch

MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.

Trial Locations (1)

Unknown

dinox GmbH, Berlin

Sponsors
All Listed Sponsors
lead

Mylan Pharmaceuticals Inc

INDUSTRY

NCT06048536 - Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch | Biotech Hunter | Biotech Hunter